114 related articles for article (PubMed ID: 12476790)
1. Molecular basis of hyperparathyroidism and potential targets for drug development.
Krebs LJ; Arnold A
Curr Drug Targets Immune Endocr Metabol Disord; 2002 Jul; 2(2):167-79. PubMed ID: 12476790
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathogenesis of primary hyperparathyroidism.
Arnold A; Shattuck TM; Mallya SM; Krebs LJ; Costa J; Gallagher J; Wild Y; Saucier K
J Bone Miner Res; 2002 Nov; 17 Suppl 2():N30-6. PubMed ID: 12412775
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetics of primary and secondary hyperparathyroidism.
Dotzenrath C; Goretzki PE; Farnebo F; Teh BT; Weber G; Röher HD; Larsson C
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():105-7. PubMed ID: 8981014
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathogenesis of primary hyperparathyroidism.
Cetani F; Pardi E; Borsari S; Marcocci C
J Endocrinol Invest; 2011 Jul; 34(7 Suppl):35-9. PubMed ID: 21985978
[TBL] [Abstract][Full Text] [Related]
5. Roles of calcium-sensing receptor and vitamin d receptor in the pathophysiology of secondary hyperparathyroidism.
McCann LM; Beto J
J Ren Nutr; 2010 May; 20(3):141-50. PubMed ID: 20303786
[TBL] [Abstract][Full Text] [Related]
6. The genetic background of uremic secondary hyperparathyroidism.
Aucella F; Morrone L; Stallone C; Gesualdo L
J Nephrol; 2005; 18(5):537-47. PubMed ID: 16299679
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid surgery in familial hyperparathyroid disorders.
Carling T; Udelsman R
J Intern Med; 2005 Jan; 257(1):27-37. PubMed ID: 15606374
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D receptor alleles b, a, and T: risk factors for sporadic primary hyperparathyroidism (HPT) but not HPT of uremia or MEN 1.
Carling T; Kindmark A; Hellman P; Holmberg L; Akerström G; Rastad J
Biochem Biophys Res Commun; 1997 Feb; 231(2):329-32. PubMed ID: 9070272
[TBL] [Abstract][Full Text] [Related]
9. Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome.
Mizusawa N; Uchino S; Iwata T; Tsuyuguchi M; Suzuki Y; Mizukoshi T; Yamashita Y; Sakurai A; Suzuki S; Beniko M; Tahara H; Fujisawa M; Kamata N; Fujisawa K; Yashiro T; Nagao D; Golam HM; Sano T; Noguchi S; Yoshimoto K
Clin Endocrinol (Oxf); 2006 Jul; 65(1):9-16. PubMed ID: 16817812
[TBL] [Abstract][Full Text] [Related]
10. Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors.
Tokumoto M; Taniguchi M; Matsuo D; Tsuruya K; Hirakata H; Iida M
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S27-34. PubMed ID: 16109139
[TBL] [Abstract][Full Text] [Related]
11. [Primary hyperparathyroidism is common among postmenopausal women. Identification of genetic risk factors can contribute to individualized treatment].
Correa P; Szabo E; Lundgren E; Carling T
Lakartidningen; 2001 May; 98(18):2198-200. PubMed ID: 11402599
[TBL] [Abstract][Full Text] [Related]
12. Calcimimetics and hyperparathyroidism.
Krebs LJ
Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
[TBL] [Abstract][Full Text] [Related]
13. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
14. The influence of the progression of secondary hyperparathyroidism on the set point of the parathyroid hormone-calcium curve.
Bas S; Aguilera-Tejero E; Bas A; Estepa JC; Lopez I; Madueño JA; Rodriguez M
J Endocrinol; 2005 Jan; 184(1):241-7. PubMed ID: 15642800
[TBL] [Abstract][Full Text] [Related]
15. [Concept, etiology and epidemiology of primary hyperparathyroidism].
Martínez Díaz-Guerra G; Hawkins Carranza F
Endocrinol Nutr; 2009 Apr; 56 Suppl 1():2-7. PubMed ID: 19627754
[TBL] [Abstract][Full Text] [Related]
16. Molecular biology of primary hyperparathyroidism.
Ferris RL; Simental AA
Otolaryngol Clin North Am; 2004 Aug; 37(4):819-31, x. PubMed ID: 15262518
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathology of parathyroid tumors.
Carling T
Trends Endocrinol Metab; 2001 Mar; 12(2):53-8. PubMed ID: 11167122
[TBL] [Abstract][Full Text] [Related]
18. Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model of primary hyperparathyroidism.
Mallya SM; Gallagher JJ; Wild YK; Kifor O; Costa-Guda J; Saucier K; Brown EM; Arnold A
Mol Endocrinol; 2005 Oct; 19(10):2603-9. PubMed ID: 15928311
[TBL] [Abstract][Full Text] [Related]
19. Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management.
Cetani F; Pardi E; Ambrogini E; Lemmi M; Borsari S; Cianferotti L; Vignali E; Viacava P; Berti P; Mariotti S; Pinchera A; Marcocci C
Clin Endocrinol (Oxf); 2006 Feb; 64(2):146-52. PubMed ID: 16430712
[TBL] [Abstract][Full Text] [Related]
20. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice.
Imanishi Y; Hosokawa Y; Yoshimoto K; Schipani E; Mallya S; Papanikolaou A; Kifor O; Tokura T; Sablosky M; Ledgard F; Gronowicz G; Wang TC; Schmidt EV; Hall C; Brown EM; Bronson R; Arnold A
J Clin Invest; 2001 May; 107(9):1093-102. PubMed ID: 11342573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
